Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Each participant will be in the study for approximately 39 weeks including: a 1-week
screening period, an 8-week (or greater) antihyperglycemic agent (AHA) wash-off period, a
2-week single-blind placebo run-in period, a 26-week double-blind treatment period, and a
post-treatment telephone contact 14 days after the last dose of study drug.

Inclusion Criteria:

- Type 2 diabetes mellitus as per American Diabetes Association guidelines

- Not on antihyperglycemic agent (AHA) >=8 weeks with a Visit 1/Screening HbA1C >=8.0%
and <=10.5% (>=64 mmol/mol and <=91 mmol/mol) OR on single allowable AHA (allowable
AHAs prior to screening are: metformin, α-glucosidase inhibitors, sulfonylureas and
glinides) with a Visit 1/Screening HbA1C >=7.5% and <=10.0% (>=58 mmol/mol and <=86
mmol/mol) OR on low-dose dual combination therapy (≤50% of maximum labeled dose of an
AHA) with allowable AHAs with a Visit 1/Screening HbA1C >=7.5% and <=10.0% (>=58
mmol/mol and <=86 mmol/mol)

- Body mass index (BMI) >=18.0 kg/m^2

- Male or female not of reproductive potential

- Female of reproductive potential who agrees to (or have their partner agree to)
remain abstinent from heterosexual activity or to use 2 acceptable combinations of
contraception.

Exclusion Criteria:

- History of type 1 diabetes mellitus or diabetic ketoacidosis

- History of other specific types of diabetes (e.g., genetic syndromes, secondary
pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and
post-organ transplant

- A known hypersensitivity or intolerance to any sodium glucose co-transporter (SGLT2)
inhibitor or sitagliptin

- Has been treated with any of the following agents within 12 weeks of study start or
during the pre-randomization period: insulin of any type (except for short-term use
[i.e., <=7 days] during concomitant illness or other stress), other injectable
anti-hyperglycemic agents (e.g., pramlintide, exenatide, liraglutide), pioglitazone
or rosiglitazone, other sodium glucose co-transporter 2 (SGLT2) inhibitors,
dipeptidyl-peptidase 4 inhibitors (DPP-4 inhibitors), bromocriptine (Cycloset™),
colesevelam (Welchol™), any other AHA with the exception of the protocol-approved
agents

- Is on a weight-loss program or weight-loss medication or other medication associated
with weight changes and is not weight stable prior to study start

- Has undergone bariatric surgery within the past 12 months or >12 months and is not
weight stable prior to study start

- A history of myocardial infarction, unstable angina, arterial revascularization,
stroke, transient ischemic attack, or New York Heart Association (NYHA) functional
Class III-IV heart failure within 3 months of study start

- Active, obstructive uropathy or indwelling urinary catheter

- History of malignancy <=5 years prior to study start, except for adequately treated
basal cell or squamous cell skin cancer or in situ cervical cancer

- A known history of human immunodeficiency virus (HIV)

- A blood dyscrasia or any disorder causing hemolysis or unstable red blood cells, or a
clinically important hematological disorder (e.g. aplastic anemia, myeloproliferative
or myelodysplastic syndromes, thrombocytopenia)

- A medical history of active liver disease (other than non-alcoholic hepatic
steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or
symptomatic gallbladder disease

- Any clinically significant malabsorption condition

- Current treatment for hyperthyroidism

- On thyroid replacement therapy and not on a stable dose for at least 6 weeks prior
study start

- On a previous clinical study with ertugliflozin

- Participated in other studies involving investigational drug(s) 30 days prior to
study start

- Surgical procedure within 6 weeks prior to study start or major surgery planned
during the trial

- Positive urine pregnancy test

- Pregnant or breast-feeding, or planning to conceive during the trial, including 14
days following the last dose of study medication

- Planning to undergo hormonal therapy in preparation for egg donation during the
trial, including 14 days following the last dose of study medication

- Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week or
engages in binge drinking

- Donated blood or blood products within 6 weeks of study start.